News
VSTM
2.960
-0.34%
-0.010
Verastem Price Target Cut to $7.00/Share From $21.00 by B. Riley Securities
Dow Jones · 2d ago
Verastem Is Maintained at Buy by B. Riley Securities
Dow Jones · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Lamb Weston, Blackstone Mortgage Trust
The Nasdaq plummeted to a one-month low on Wednesday after Tesla and Alphabet disappointed with lackluster earnings. The Dow Jones Industrial Average was down 0.74% and the S&P 500 was down 1.62%. Tesla, Lamb Weston, Blackstone Mortgage Trust were among the biggest losers.
Reuters · 2d ago
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
General Dynamics Corporation shares fell 5.2% to $279.26 on Wednesday. The company reported worse-than-expected second-quarter EPS results. NuZee, Inc. Shares jumped 192% after falling over 22% on Tuesday. Other stocks moving in the mid-day session included Tenet Healthcare Corporation and Mattel.
Benzinga · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-FTAI Aviation, Check Point, Sage Therapeutics
Dow Jones Industrial Average was down 0.78% on Wednesday. The tech-heavy Nasdaq leading declines after lackluster quarterly results from Tesla and Alphabet. The top three S&P 500 percentage gainers were Enphase Energy, AT&T and Check Point Software. FTAI Aviation, Check Point, Sage Therapeutics were up on the day.
Reuters · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Estee Lauder, Enphase, GE Vernova
Wall Street futures fall on Wednesday after weak quarterly earnings from Tesla and Alphabet. Estee Lauder, Enphase, GE Vernova are among the top gainers on the NYSE. Dow e-minis were down 0.34% and S&P 500 and Nasdaq 100 futures also down.
Reuters · 2d ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Dermata Therapeutics stock is rocketing more than 123% alongside heavy pre-market trading. Biggest Pre-Market Stock Movers: 10 Top Gainers and 10 Top Losers for Wednesday morning. A new partnership, a public offering, clinical trial news and more are moving stocks this morning.
Investorplace · 2d ago
VERASTEM INC <VSTM.O>: B. RILEY CUTS TARGET PRICE TO $7 FROM $21 POST COMPANY'S EQUITY OFFERING
Reuters · 2d ago
BUZZ-Verastem sinks on $55 mln stock-and-warrants offering
Verastem's VSTM.O shares down 26.2% premarket to $2.65 after biopharma firm's overnight equity offering priced. Oncology-focused firm sells $55 mln stock-and-warrants offering. Shares have shed 56% YTD through Tues.
Reuters · 2d ago
Why Enphase Energy Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Enphase Energy, Inc. Shares rose sharply in today's pre-market trading after the company reported second-quarter financial results. The company reported adjusted earnings of 43 cents per share, missing analyst estimates of 48 cents. Dermata Therapeutics, Inc., shares rose 146.2% to $3.20 after falling over 22% on Tuesday.
Benzinga · 2d ago
U.S. RESEARCH ROUNDUP-Alphabet, GE Aerospace, Tesla
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Alphabet, GE Aerospace and Tesla are among the companies. GE Aerospace raises target price to $190 from $175; Kimberly-Clark raises price target to $137. Apple, AT&T and Apple suppliers also see their targets revised up.
Reuters · 2d ago
Verastem Oncology slumps 26%, prices $55M offering
Verastem Oncology slumps 26%, prices $55M offering of shares and warrants. The stock price dipped 26% on Tuesday during after hours trading. The gross proceeds from the offering are expected to be $55 million. Verastem oncology is a biopharmaceutical company.
Seeking Alpha · 2d ago
Reported Earlier, Verastem Oncology Prices $55M Public Offering Of 13,333,334 Common Stock, Warrants And Pre-Funded Warrants
Verastem Oncology announced pricing of an underwritten public offering of 13,333,334 shares of its common stock. The company is a biopharmaceutical company committed to advancing new medicines for patients with cancer. The warrants have an exercise price of $3.50 per share.
Benzinga · 2d ago
Verastem Oncology Announces Pricing Of $55.0 Mln Offering Of Common Stock, Warrants
NASDAQ · 3d ago
*Verastem To Use Proceeds to Fund Potential Product Launches >VSTM
Dow Jones · 3d ago
*Verastem Offered Pre-Funded Warrants for 5M Shrs to Certain Investors >VSTM
Dow Jones · 3d ago
*Verastem: Guggenheim Securities, Cantor Acting as Book-Running Managers >VSTM
Dow Jones · 3d ago
*Verastem Warrants Have Exercise Price of $3.50 Per Share >VSTM
Dow Jones · 3d ago
*Verastem: 13,333,334 Shares, Accompanying Warrants Offered at Combined Price of $3.00 Each >VSTM
Dow Jones · 3d ago
VERASTEM INC - PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 13.3 MLN SHARES AT $3.00 PER SHARE
Reuters · 3d ago
More
Webull provides a variety of real-time VSTM stock news. You can receive the latest news about Verastem through multiple platforms. This information may help you make smarter investment decisions.
About VSTM
Verastem, Inc. is a late-stage development biopharmaceutical company. The Company's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Company’s advanced product candidates, avutometinib and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer (CRC), and melanoma. Avutometinib is an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma (RAS)/RAF/MEK, ERK mitogen activated pathway kinase (MAPK) pathway. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2).